Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

BLTE

Belite Bio (BLTE)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BLTE
DataOraFonteTitoloSimboloCompagnia
21/11/202400:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
12/11/202407:00GlobeNewswire Inc.Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:BLTEBelite Bio Inc
05/11/202414:00GlobeNewswire Inc.Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
04/11/202412:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLTEBelite Bio Inc
03/11/202422:00GlobeNewswire Inc.Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross ProceedsNASDAQ:BLTEBelite Bio Inc
14/10/202414:00GlobeNewswire Inc.Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingNASDAQ:BLTEBelite Bio Inc
08/10/202423:48Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:BLTEBelite Bio Inc
08/10/202414:00GlobeNewswire Inc.Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual SummitNASDAQ:BLTEBelite Bio Inc
01/10/202412:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLTEBelite Bio Inc
26/09/202414:51GlobeNewswire Inc.Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:BLTEBelite Bio Inc
17/09/202417:22GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:BLTEBelite Bio Inc
10/09/202414:00GlobeNewswire Inc.Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt DiseaseNASDAQ:BLTEBelite Bio Inc
03/09/202414:00GlobeNewswire Inc.Belite Bio to Participate in Three Upcoming Investor ConferencesNASDAQ:BLTEBelite Bio Inc
01/09/202414:00GlobeNewswire Inc.Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical OfficerNASDAQ:BLTEBelite Bio Inc
09/08/202422:30GlobeNewswire Inc.Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:BLTEBelite Bio Inc
08/08/202414:00GlobeNewswire Inc.Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:BLTEBelite Bio Inc
06/08/202401:10GlobeNewswire Inc.Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
08/07/202414:00GlobeNewswire Inc.Belite Bio to Present at the JonesHealthcare Seaside SummitNASDAQ:BLTEBelite Bio Inc
12/06/202408:55GlobeNewswire Inc.Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in JapanNASDAQ:BLTEBelite Bio Inc
14/05/202414:00GlobeNewswire Inc.Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor ConferenceNASDAQ:BLTEBelite Bio Inc
14/05/202403:50GlobeNewswire Inc.Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:BLTEBelite Bio Inc
13/05/202414:00GlobeNewswire Inc.Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:BLTEBelite Bio Inc
08/05/202414:00GlobeNewswire Inc.Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
06/05/202414:15GlobeNewswire Inc.Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantNASDAQ:BLTEBelite Bio Inc
06/05/202414:00GlobeNewswire Inc.Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingNASDAQ:BLTEBelite Bio Inc
01/05/202422:15GlobeNewswire Inc.Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:BLTEBelite Bio Inc
26/04/202401:15GlobeNewswire Inc.Belite Bio Announces $25 Million Registered Direct OfferingNASDAQ:BLTEBelite Bio Inc
22/03/202413:00GlobeNewswire Inc.Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanNASDAQ:BLTEBelite Bio Inc
12/03/202403:28GlobeNewswire Inc.Belite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteNASDAQ:BLTEBelite Bio Inc
12/03/202402:27GlobeNewswire Inc.Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:BLTEBelite Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BLTE
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network